---
title: Mike Steigerwald shared a link.
date: '2019-07-23T14:27:14.000Z'
platform: facebook
source_file: your_posts__check_ins__photos_and_videos_1.json
---
What gives: As the dominant providers of dialysis care in the U.S., Fresenius and DaVita together form what health economists call a "duopoly." They can demand extraordinary prices for the lifesaving treatment they dispense â especially when they are not in a patient's network. A 1973 law allows all patients with end-stage renal disease like Sov to join Medicare, even if they're younger than 65 â but only after a 90-day waiting period. During that time, patients are extremely vulnerable, medically and financially.
